Skip to content

Moderna MRNA Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
ALN
Alnylam PharmaceuticalsALNY
15%+12.7pp
Roivant Sciences logo
Roivant SciencesROIV
-9,183.5%-17,093pp
Biogen logo
BiogenBIIB
24.4%-0.4pp
Merck & Co. logo
Merck & Co.MRK
21.5%-5.2pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.5%-4.3pp

Other financials

Income statement

See full
Revenue$389.0M+260%
Gross profit-$566.0M-3,244%
Operating income-$1.4B-32.2%
Net income-$1.3B-38.3%
EPS (diluted)-$3.40-34.9%

Balance sheet

See full
Cash & equivalents$1.9B+17.4%
Total debt$1.3B+71.9%
Total equity$7.4B-26.4%
Total assets$11.5B-9.6%

Cash flow

See full
Operating cash flow-$630.0M+39.3%
CapEx$62.0M-47.0%
Free cash flow-$692.0M+40.0%

Valuation

See full
Market cap$25.38B+83.8%
Enterprise value$24.8B+93.6%
P/S11.4×+7.1×

Profitability

See full
Gross margin22.1%-32.0pp
Operating margin-153.3%+67.8pp
Net margin-143.6%+80.2pp

Returns & leverage

See full
Return on equity-36.6%+11.9pp
Debt / equity0.2×+0.1×
Current ratio2.4×-1.8×

Where this comes from

Calculated from Moderna’s reported figures.

Based on trailing twelve months.

The official record: Moderna’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Moderna's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Moderna's free cash flow margin?
Moderna (MRNA) reported free cash flow margin of -132.4% in Q3 2025.
What does free cash flow margin mean?
How much real, spendable cash each sales dollar generates after reinvestment.
How do you interpret free cash flow margin?
A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
How does free cash flow margin compare across companies?
Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.